Document:

exv10w36xay

Exhibit 10.36(a)

ONCOTHYREON INC.

NOTE AMENDMENT AGREEMENT

     This Note Amendment Agreement (this “Agreement”) is made as of this 20th day of
April 2008, by and between Oncothyreon Inc., formerly known as Biomira Inc., (the “Company”) and
Jeffrey Millard (“Employee”).

     WHEREAS, Employee has executed that certain Promissory Note, dated November 8, 2006 (the
“Note”), in an original principal amount of US$127,391, in favor of the Company;

     WHEREAS, Employee and the Company entered into a Security Agreement dated November 8, 2006
(the “Security Agreement”) and a General Security Agreement dated November 8, 2006 (the “General
Security Agreement” and together with the Security Agreement, the “Security Agreements”) pursuant
to which Employee pledged his Pledged Securities, as such term is defined in the Security
Agreement, as collateral for his obligations under the Note;

     WHEREAS, Employee and the Company desire to extend the maturity of the Note as an incentive to
Employee to continue employment with the Company; and

     WHEREAS, Employee and the Company have considered the current market interest rates as
compared to the rates at the time the Note was executed and agree that the reasonable interest rate
on the Note is still 5.0% per annum.

NOW, THEREFORE, in consideration of the mutual promises made herein, the parties hereby agree as
follows:

1 Amendment to Note.

          1.1 Amendment of Maturity Date. The first sentence of Section 2 of the Note shall be
amended and restated in its entirety to read as follows: “The principal amount of this Promissory
Note, together with interest accrued to the date of payment, is due and payable by Debtor on the
earlier of (i) April 28, 2011 and (ii) the last date Employee is employed by the Company (the
“Maturity Date”).” Except for such amendment, the provisions of the Note shall remain unchanged
and shall continue in full force and effect.

2 Additional Provisions.

          2.1 Severability. In the event that any provision hereof becomes or is declared by a
court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue
in full force and effect without said provision.

          2.2 No Oral Modification. This Agreement may only be amended in writing signed by the
Party against whom the amendment is being sought.

          2.3 Counterparts. This Agreement may be executed in counterparts, and each
counterpart shall have the same force and effect as an original and shall constitute an effective,

 

 

binding agreement on the part of each of the undersigned. Execution and delivery of this
Agreement by exchange of facsimile copies bearing the facsimile signature of a party shall
constitute a valid and binding execution and delivery of the Agreement by such party. Such
facsimile copies shall constitute enforceable original documents.

          2.4 Prior Agreements. This Agreement and the Note supersede in their entirety all
prior agreements relating to the Note, written or oral.

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first set forth
above.

	 	 	 	 	 
	 	ONCOTHYREON INC.

 	 
	 	By:  	/s/ Robert L. Kirkman, M.D.
 	 
	 	 	     Robert L. Kirkman, M.D.
	 
	 	 	     President and Chief Executive Officer 	 
	 
	 	EMPLOYEE

 	 
	 	/s/ Jeffrey Millard
 	 
	 	Jeffrey Millard 	 
	 	 	 
	 

2exv10w37xay

Exhibit 10.37(a)

ONCOTHYREON INC.

NOTE AMENDMENT AGREEMENT

     This Note Amendment Agreement (this “Agreement”) is made as of this 20th day of
April 2008, by and between Oncothyreon Inc., formerly known as Biomira Inc., (the “Company”) and
Linda Pestano (“Employee”).

     WHEREAS, Employee has executed that certain Promissory Note, dated November 8, 2006 (the
"Note”), in an original principal amount of US$66,889, in favor of the Company;

     WHEREAS, Employee and the Company entered into a Security Agreement dated November 8, 2006
(the “Security Agreement”) and a General Security Agreement dated November 8, 2006 (the “General
Security Agreement” and together with the Security Agreement, the “Security Agreements”) pursuant
to which Employee pledged her Pledged Securities, as such term is defined in the Security
Agreement, as collateral for her obligations under the Note; and

     WHEREAS, Employee and the Company desire to extend the maturity of the Note as an incentive to
Employee to continue employment with the Company; and

     WHEREAS, Employee and the Company have considered the current market interest rates as
compared to the rates at the time the Note was executed and agree that the reasonable interest rate
on the Note is still 5.0% per annum.

     NOW, THEREFORE, in consideration of the mutual promises made herein, the parties hereby agree as
follows:

1 Amendment to Note.

          1.1 Amendment of Maturity Date. The first sentence of Section 2 of the Note shall be
amended and restated in its entirety to read as follows: “The principal amount of this Promissory
Note, together with interest accrued to the date of payment, is due and payable by Debtor on the
earlier of (i) April 28, 2010 and (ii) the last date Employee is employed by the Company (the
“Maturity Date”).” Except for such amendment, the provisions of the Note shall remain unchanged
and shall continue in full force and effect.

2 Additional Provisions.

          2.1 Severability. In the event that any provision hereof becomes or is declared by a
court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue
in full force and effect without said provision.

          2.2 No Oral Modification. This Agreement may only be amended in writing signed by the
Party against whom the amendment is being sought.

          2.3 Counterparts. This Agreement may be executed in counterparts, and each
counterpart shall have the same force and effect as an original and shall constitute an effective,

 

binding agreement on the part of each of the undersigned. Execution and delivery of this
Agreement by exchange of facsimile copies bearing the facsimile signature of a party shall
constitute a valid and binding execution and delivery of the Agreement by such party. Such
facsimile copies shall constitute enforceable original documents.

          2.4 Prior Agreements. This Agreement and the Note supersede in their entirety all
prior agreements relating to the Note, written or oral.

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first set forth
above.

	 	 	 	 	 
	 	ONCOTHYREON INC.

 	 
	 	By:  	/s/ Robert L. Kirkman, M.D.
 	 
	 	 	Robert L. Kirkman, M.D. 	 
	 	 	President and Chief Executive Officer 	 
	 
	 	EMPLOYEE

 	 
	 	/s/ Linda Pestano
 	 
	 	Linda Pestano 	 
	 	 	 
	 

2exv10w40xay

Exhibit 10.40(a)

ONCOTHYREON INC.

AMENDMENT TO GARY CHRISTIANSON OFFER LETTER

     This amendment (the “Amendment”) is made by and between Gary Christianson (“Executive”) and
Oncothyreon Inc. (formerly Biomira Inc.), a Delaware corporation (the “Company” and together with
the Executive hereinafter collectively referred to as the “Parties”) on December 31, 2008.

WITNESSETH:

     WHEREAS, the Parties previously entered into an offer letter, dated June 29, 2007 (the “Offer
Letter”); and

     WHEREAS, the Company and Executive desire to amend certain provisions of the Offer Letter in
order to come into documentary compliance with Section 409A of the Internal Revenue Code of 1986,
as amended (the “Code”), and any final regulations and official guidance promulgated thereunder
(together, “Section 409A”) so as to avoid the imposition of the additional tax imposed under
Section 409A, as set forth below.

     NOW, THEREFORE, for good and valuable consideration, Executive and the Company agree that the
Offer Letter is hereby amended as follows:

1. Severance. Section 5 of the Offer Letter is hereby amended to add the following to the
end thereof:

          “Section 409A.

          (i) Notwithstanding anything to the contrary in this letter agreement, no severance
payable to you, if any, pursuant to this letter agreement that, when considered together
with any other severance payments or separation benefits, are considered deferred
compensation under Section 409A of the Internal Revenue Code of 1986, as amended, and
any final regulations and official guidance promulgated thereunder (together, “Section
409A”) (together, the “Deferred Payments”) will be payable until you have a “separation
from service” within the meaning of Section 409A. Similarly, no severance payable to
you, if any, pursuant to this letter agreement that otherwise would be exempt from
Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be payable
until you have a “separation from service” within the meaning of Section 409A.

          (ii) Notwithstanding anything to the contrary in this letter agreement, if you are
a “specified employee” within the meaning of Section 409A at the time of your separation
from service, then, if required, the Deferred Payments, which are otherwise due to you
on or within the six (6) month period following your separation from service will
accrue, to the extent required, during such six (6) month period and will become payable
in a lump sum payment on the date six (6) months and one (1) day following the date of
your separation from service or the date of your death, if earlier.

 

 

All subsequent Deferred Payments, if any, will be payable in accordance with the
payment schedule applicable to each payment or benefit. Each payment and benefit
payable under this letter agreement is intended to constitute a separate payment for
purposes of Treasury Regulation Section 1.409A-2(b)(2).

          (iii) Any amount paid under the letter agreement that satisfies the requirements of
the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury
Regulations will not constitute Deferred Payments for purposes of clause (i) above.

          (iv) Any amount paid under this letter agreement that qualifies as a payment made
as a result of an involuntary separation from service pursuant to Section
1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A
Limit will not constitute Deferred Payments for purposes of clause (i) above. “Section
409A Limit” will mean the lesser of two (2) times: (i) your annualized compensation
based upon the annual rate of pay paid to you during your taxable year preceding your
taxable year of your termination of employment as determined under Treasury Regulation
Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with
respect thereto; or (ii) the maximum amount that may be taken into account under a
qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year
in which your employment is terminated.

          (v) The foregoing provisions are intended to comply with the requirements of
Section 409A so that none of the severance payments and benefits to be provided
hereunder will be subject to the additional tax imposed under Section 409A, and any
ambiguities herein will be interpreted to so comply. You and the Company agree to work
together in good faith to consider amendments to this letter agreement and to take such
reasonable actions which are necessary, appropriate or desirable to avoid imposition of
any additional tax or income recognition prior to actual payment to you under Section
409A.”

2. Relocation. Section 8 of the Offer Letter is hereby amended to add the following
sentence to the end thereof:

“Any such Company provided or paid relocation expenses are subject to your continued
employment with the Company through the payment date.”

3. Full Force and Effect. To the extent not expressly amended hereby, the Offer Letter
shall remain in full force and effect.

4. Entire Agreement. This Amendment and the Offer Letter constitute the full and entire
understanding and agreement between the Parties with regard to the subjects hereof and thereof.
This Amendment may be amended at any time only by mutual written agreement of the Parties.

-2-

 

5. Counterparts. This Amendment may be executed in counterparts, all of which together
shall constitute one instrument, and each of which may be executed by less than all of the parties
to this Amendment.

6. Governing Law. This Amendment will be governed by the laws of the State of Washington
(with the exception of its conflict of laws provisions).

-3-

 

     IN WITNESS WHEREOF, each of the Parties has executed this Amendment, in the case of the
Company by its duly authorized officer, as of the date set forth above.

	 	 	 	 	 	 	 
	COMPANY	 	ONCOTHYREON INC.
	 
	 	 	 	 	 	 
	 
	 	/s/ Robert L. Kirkman, M.D.	 	 
	 

	 	 
	 	 	 	 
	 
	 	By:	 	Robert L. Kirkman, M.D.	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	President and Chief Executive Officer	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	EXECUTIVE	 	GARY CHRISTIANSON
	 
	 	 	 	 	 	 
	 
	 	/s/ Gary Christianson	 	 
	 

	 	 
	 	 	 	 

-4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]